{
    "clinical_study": {
        "@rank": "65499", 
        "brief_summary": {
            "textblock": "Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene\n      (RLX) and bazedoxifene (BZA), the difference is still unclear.  In this study, we plan to\n      compare clinical efficacy and safety between RLX and BZA."
        }, 
        "brief_title": "Comparison Between Raloxifene and Bazedoxifene", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Selective Estrogen Receptor Modulator", 
        "detailed_description": {
            "textblock": "Selective estrogen receptor modulator (SERM) is an important option for postmenopausal\n      osteoporosis. There are two SERM approved in Japan for the treatment of postmenopausal\n      osteoporosis in women at increased risk of fracture. One is raloxifene (RLX), and the other\n      is bazedoxifene (BZA). There are few reports concerning to the clinical efficacy and safety\n      data. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.\n\n      The main objective of this study is to reveal the effects of RLX and BZA on bone mineral\n      density, bone turnover markers, and bone quality markers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal women\n\n        Exclusion Criteria:\n\n          -  Patients who could not use SERM"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Osteoporosis patients using SERM more for five years."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973738", 
            "org_study_id": "IRB TH 05"
        }, 
        "intervention_browse": {
            "mesh_term": "Raloxifene"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "raloxifene", 
            "bazedoxifene", 
            "bone mineral density", 
            "bone turnover markers", 
            "bone quality"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "contact": {
                "email": "furikakefuri@hotmail.co.jp", 
                "last_name": "Rui Niimi, MD, PhD", 
                "phone": "(81)-59-365-0023"
            }, 
            "facility": {
                "address": {
                    "city": "Yokkaichi", 
                    "country": "Japan", 
                    "state": "Mie", 
                    "zip": "510-8008"
                }, 
                "name": "Tomidahama Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Comparison of the Clinical Efficacy and Safety Between Raloxifene and Bazedoxifene in Postmenopausal Women.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The investigators plan to analyze 300 patients who undergo selective estrogen receptor modulator (SERM) treatments for five years.\nWe investigate the efficacy of two SERMs: raloxifene (RLX) and bazedoxifene (BZA). Bone mineral density (BMD) andd laboratory analyses (bone markers, routine chemistry, urine, and bone quality marker of pentosidine) at baseline and every four to six months. We also investigate the side effects.   Statical analyses are performed using Spearman correlation coefficients, paired t-test, Mann-Whitney U test, chi-square test and Fisher's exact test to compare the efficacy and safy between RLX and BZA.", 
            "measure": "Effects of raloxifene vs. bazedoxifene on bone mineral density, bone turnover markers and bone quality markers in postmenopausal osteoporosis.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 72 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973738"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tomidahama Hospital", 
            "investigator_full_name": "Toshihiko Kono", 
            "investigator_title": "Head of Hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Tomidahama Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Toshihiko Kono", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}